Current partner codePEPTIDESDE
Evidence dashboardStudies since 1999Updated Jul 31, 2026

SecretinClinical Trials.

A source-linked view of every Secretin study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.

Total trials
53
Recruiting
5
Completed
26
Terminated
6
Results posted
8
Average enrollment
279
Countries
9
Highest phase
Phase 4

Developer / research origin

Multiple

Evidence summary

Activity is not efficacy.

Secretin appears in 53 indexed studies: 5 recruiting, 26 completed and 8 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Secretin is safe or effective.

Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.

Development history

Trial timeline.

Evidence timeline

19992026

Velocity

Secretin studies by start year

Study start year · indexed snapshot

4321019991999: 1 trials2000: 0 trials2001: 0 trials2002: 2 trials2003: 0 trials20042004: 0 trials2005: 4 trials2006: 3 trials2007: 2 trials2008: 4 trials20092009: 2 trials2010: 3 trials2011: 2 trials2012: 3 trials2013: 1 trials20142014: 2 trials2015: 1 trials2016: 2 trials2017: 3 trials2018: 4 trials20192019: 0 trials2020: 2 trials2021: 1 trials2022: 2 trials2023: 2 trials20242024: 4 trials2025: 2 trials20262026: 1 trials

Development

Trials by phase

Early Phase 12
Phase 110
Phase 212
Phase 310
Phase 43

Current studies

Recruiting or active

Completed studies

Finished records

Stopped studies

Withdrawn or terminated

Showing 6 of 12 studies
Showing 6 of 26 studies
Showing 6 of 11 studies

Full study index

Search Secretin trials.

Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.

53 matching studies

Latest publications

Follow the paper trail.

PMID 36721302de Jong IEM, Bodewes SB, van Leeuwen OB, Oosterhuis D, Lantinga VA, Thorne AM, Lascaris B, van den Heuvel MC, Wells RG, Olinga P, de Meijer VE, Porte RJ. Restoration of Bile Duct Injury of Donor Livers During Ex Situ Normothermic Machine Perfusion. Transplantation. 2023 Jun 1;107(6):e161-e172. doi: 10.1097/TP.0000000000004531. Epub 2023 May 23.Linked from NCT07651748PMID 36740047Eden J, Sousa Da Silva R, Cortes-Cerisuelo M, Croome K, De Carlis R, Hessheimer AJ, Muller X, de Goeij F, Banz V, Magini G, Compagnon P, Elmer A, Lauterio A, Panconesi R, Widmer J, Dondossola D, Muiesan P, Monbaliu D, de Rosner van Rosmalen M, Detry O, Fondevila C, Jochmans I, Pirenne J, Immer F, Oniscu GC, de Jonge J, Lesurtel M, De Carlis LG, Taner CB, Heaton N, Schlegel A, Dutkowski P. Utilization of livers donated after circulatory death for transplantation - An international comparison. J Hepatol. 2023 May;78(5):1007-1016. doi: 10.1016/j.jhep.2023.01.025. Epub 2023 Feb 4.Linked from NCT07651748PMID 25939487Orman ES, Mayorga ME, Wheeler SB, Townsley RM, Toro-Diaz HH, Hayashi PH, Barritt AS 4th. Declining liver graft quality threatens the future of liver transplantation in the United States. Liver Transpl. 2015 Aug;21(8):1040-50. doi: 10.1002/lt.24160.Linked from NCT07651748PMID 26831547Nemes B, Gaman G, Polak WG, Gelley F, Hara T, Ono S, Baimakhanov Z, Piros L, Eguchi S. Extended-criteria donors in liver transplantation Part II: reviewing the impact of extended-criteria donors on the complications and outcomes of liver transplantation. Expert Rev Gastroenterol Hepatol. 2016 Jul;10(7):841-59. doi: 10.1586/17474124.2016.1149062. Epub 2016 Mar 2.Linked from NCT07651748PMID 35286759van Leeuwen OB, Bodewes SB, Lantinga VA, Haring MPD, Thorne AM, Bruggenwirth IMA, van den Berg AP, de Boer MT, de Jong IEM, de Kleine RHJ, Lascaris B, Nijsten MWN, Reyntjens KMEM, de Meijer VE, Porte RJ. Sequential hypothermic and normothermic machine perfusion enables safe transplantation of high-risk donor livers. Am J Transplant. 2022 Jun;22(6):1658-1670. doi: 10.1111/ajt.17022. Epub 2022 Apr 18.Linked from NCT07651748PMID 23720296Tabibian JH, Masyuk AI, Masyuk TV, O'Hara SP, LaRusso NF. Physiology of cholangiocytes. Compr Physiol. 2013 Jan;3(1):541-65. doi: 10.1002/cphy.c120019.Linked from NCT07651748PMID 21932391Hohenester S, Wenniger LM, Paulusma CC, van Vliet SJ, Jefferson DM, Elferink RP, Beuers U. A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology. 2012 Jan;55(1):173-83. doi: 10.1002/hep.24691.Linked from NCT07651748PMID 36191836Yadav D, Askew RL, Palermo T, Li L, Andersen DK, Chen M, Fisher WE, Fogel EL, Forsmark CE, Hart PA, Othman MO, Pandol SJ, Park WG, Topazian MD, Van Den Eeden SK, Vege SS, Yang Y, Serrano J, Conwell DL; Consortium for the Study of Chronic Pancreatitis, Diabetes; Pancreatic Cancer (CPDPC). Association of Chronic Pancreatitis Pain Features With Physical, Mental, and Social Health. Clin Gastroenterol Hepatol. 2023 Jul;21(7):1781-1791.e4. doi: 10.1016/j.cgh.2022.09.026. Epub 2022 Oct 1.Linked from NCT03099850

Related pages

Keep researching Secretin.

Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.